Clinical trial

Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage

NCT00198497 · Bausch & Lomb Incorporated, Industry · Completed

Key facts

NCT number NCT00198497
Title Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage
Official title Phase III Safety and Efficacy Study of Vitrase (Ovine Hyaluronidase) for Ophthalmic Intravitreal Injection for Clearance of Severe Vitreous Hemorrhage
Lead sponsor Bausch & Lomb Incorporated, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Vitreous Hemorrhage, Diabetic Retinopathy
Intervention type Drug
Interventions Placebo, Vitrase
Enrollment 510
Start date Jun 1, 1999
Primary completion Sep 1, 2001
Completion Jun 1, 2003
First posted Sep 20, 2005
Last update posted Mar 15, 2013
Countries Australia, Brazil, Hungary, Italy, Netherlands, Poland, South Africa, Spain, United Kingdom

At a glance

  • 10–99 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies